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Abstract
Current regimens for induction therapy of pediatric acute lymphoblastic leukemia (ALL), or for re-induction post relapse, use
a combination of vincristine (VCR), a glucocorticoid, and L-asparaginase (ASP) with or without an anthracycline. With cure
rates now approximately 80%, robust pre-clinical models are necessary to prioritize active new drugs for clinical trials in
relapsed/refractory patients, and the ability of these models to predict synergy/antagonism with established therapy is an
essential attribute. In this study, we report optimization of an induction-type regimen by combining VCR, dexamethasone
(DEX) and ASP (VXL) against ALL xenograft models established from patient biopsies in immune-deficient mice. We
demonstrate that the VXL combination was synergistic in vitro against leukemia cell lines as well as in vivo against ALL
xenografts. In vivo, VXL treatment caused delays in progression of individual xenografts ranging from 22 to .146 days. The
median progression delay of xenografts derived from long-term surviving patients was 2-fold greater than that of
xenografts derived from patients who died of their disease. Pharmacokinetic analysis revealed that systemic DEX exposure
in mice increased 2-fold when administered in combination with VCR and ASP, consistent with clinical findings, which may
contribute to the observed synergy between the 3 drugs. Finally, as proof-of-principle we tested the in vivo efficacy of
combining VXL with either the Bcl-2/Bcl-xL/Bcl-w inhibitor, ABT-737, or arsenic trioxide to provide evidence of a robust in
vivo platform to prioritize new drugs for clinical trials in children with relapsed/refractory ALL.
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Introduction
Leukemia is the most common childhood malignancy, account-
ing for a third of all pediatric cancers and ALL comprises
approximately 80% of all leukemia cases in children [1] The
prognosis for children diagnosed with ALL has improved
markedly during the past 50 years, and current protocols utilizing
VCR, a glucocorticoid, and ASP to treat ALL result in over 95%
of children entering complete remission with 5-year survival rates
of approximately 80% [1].
Despite significant improvements in therapy and supportive
care, relapsed ALL is the fifth most prevalent pediatric cancer, and
ALL remains the most common cause of death from malignancy
in children [2,3]. For those children who suffer an early relapse in
the bone marrow, the prospects for long-term survival are dismal,
with the best therapeutic option being hematopoietic stem cell
transplantation following induction into second remission. How-
ever, in some instances, patients are unable to achieve a second
remission [4]. Certain ALL subtypes that are associated with
specific chromosomal translocations (e.g. t9;22 and t4;11) remain
exceptionally difficult to cure [5,6]. Moreover, current chemo-
therapy regimens are associated with morbidity and long-term side
effects such as infertility, impaired mental and physical develop-
ment, and a greater risk of cancer later in life [7,8].
While increases in pediatric ALL cure rates have principally
been invoked through a better use of existing drugs and
improvements in supportive care, dozens of new drugs that are
being developed primarily to treat adult cancers are potentially
available for pediatric clinical trials. However, neither sufficient
numbers of pediatric patients are available to test all of these new
drugs, nor it is ethical to conduct such trials without strong
supporting preclinical data. There is evidence to suggest that
future ALL treatment protocols will incorporate new agents into
established therapies [9] emphasizing the need for appropriate
preclinical multi-agent chemotherapy models. These experimental
models should also be able to assess the effects of novel agents
when used in combination with standard induction therapy drugs,
either to facilitate induction into second remission prior to
hematopoietic stem cell transplantation of chemotherapy refrac-
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effects of standard therapy.
The attrition rate of potential anti-cancer drugs entering clinical
trial is very high, with one study reporting only 5% of agents
gaining US FDA approval in 1991–2000 [10]. While the reasons
for drug failure in the clinic are likely to be multifactorial,
retrospective analysis of pharmacokinetic and pharmacodynamic
parameters comparing pre-clinical and clinical data supports the
notion that these are crucial in determining efficacy [11]. The
distribution and metabolism of certain drugs in different
compartments and organs in experimental animals can differ
significantly from that of humans, as noted in studies using
cyclophosphamide [12], methotrexate [12], topotecan [13] or
irofulven [11]. Therefore, to improve predictability of therapeutic
efficacy of drugs in humans, pharmacokinetic studies should be
conducted during in vivo drug testing in order to assess drug
disposition in the experimental animal, and adjustments to the
drug dose may be necessary to treat the animal at similar systemic
exposures to model those used in the clinic.
The non-obese diabetic/severe combined immunodeficient
(NOD/SCID) mouse strain is highly receptive to engraftment of
human ALL primary biopsy specimens [14,15,16]. Moreover,
xenografted human cells infiltrate bone marrow, spleen and liver,
and blasts in the peripheral blood (PB) retain the morphological
characteristics of the original disease [17,18]. An additional
advantage of the orthotopic NOD/SCID mouse model of ALL
is that it allows for monitoring disease burden and response to
chemotherapeutic drugs in ‘‘real-time’’ by serial sampling of PB
[17,18,19]. We have previously reported that the in vivo responses
of a panel of xenografts established from pediatric ALL biopsy
specimens to single-agent VCR or DEX significantly correlated
with the clinical outcome of the patients from whom the xenografts
were derived [17]. Therefore, this experimental model appears
highly relevant for the testing of novel treatment strategies.
The aim of this study was to use the xenograft models of
pediatric ALL established as systemic disease in NOD/SCID mice
in order to: A) use an induction-type regimen of VXL combination
therapy in order to induce partial remissions in aggressive and
chemoresistant xenografts; B) simultaneously analyze the pharma-
cokinetics of these drugs (as single agents and in combination) in
the NOD/SCID mouse to ensure the clinical relevance of these
treatments; and C) assess in vivo interactions between VXL and the
BH3 mimetic ABT-737 [20] or arsenic trioxide (ATO) with the
objective of validating this model for the evaluation of additional
compounds in combination with the VXL backbone to facilitate
decision making for their incorporation into induction and re-
induction protocols and/or dose-sparing regimens.
Figure 1. Synergy between VCR, DEX and ASP against ALL cell lines   n vitro. Cell lines were exposed to VCR (open circles), DEX (open
triangles), ASP (open squares), or the triple combination VXL (closed circles), at fixed ratios, and dose-responses were assessed using the DIMSCAN
assay as described in Materials and methods. Fractional survival of treated vs. untreated control cells is shown. Each condition included 12 replicates
and error bars represent standard deviation. The data shown are representative of two independent experiments.
doi:10.1371/journal.pone.0033894.g001
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Synergy of VXL combination against ALL cell lines in vitro
In order to assess the interactions between VCR, DEX and ASP
against ALL cell lines in vitro, we examined the cytotoxicity profiles
of 4 ALL cell lines (CCRF-CEM, COG-LL-317, COG-LL-319
and RS4-11) exposed to VCR, DEX, ASP and the triple-drug
combination (VXL) (Figure 1). Although the ALL cell lines
exhibited varied sensitivity to VCR, DEX, and ASP, the
combination of the 3 drugs consistently displayed synergistic
interactions at all drug concentrations tested, with the only
exception being the CEM cell line exposed to the highest drug
concentrations (Figure 1 and Table 1). With this minor exception
aside, the calculated CI values indicate strong synergy between the
3 drugs in vitro with a common trend towards stronger synergy at
lower combination concentrations for the cell lines CEM, COG-
LL-317 and COG-LL-319 (Table 1).
Real-time monitoring of leukemia engraftment and
response to therapy
Figure S1 represents leukemia infiltration of bone marrow,
spleen, liver and PB at weekly intervals following inoculation of
NOD/SCID mice with xenograft ALL-19, and confirms that
monitoring %huCD45
+ cells in the PB provides a reliable
representation of overall leukemic burden in the animal, in
agreement with a previous report [19]. Engraftment and response
to therapy in all subsequent experiments were monitored by
weekly enumeration of the %huCD45
+ cells in the PB.
Optimization of the VXL regimen using in vivo childhood
ALL xenograft models
We have previously determined the in vivo VCR and DEX
sensitivities of a panel of childhood ALL continuous xenografts
derived from primary patient biopsies (details of patient charac-
teristics are included in Table S1) [17]. In order to develop
combination chemotherapy protocols that mimic induction
regimens administered to pediatric ALL patients, it was also
necessary to determine the in vivo efficacy of ASP as single agent.
For these and subsequent experiments ASP was administered
Mon-Fri for 4 weeks in an attempt to mimic the dosing schedule
administered to patients. ASP at a dose of 2500 U/kg delayed the
progression of ALL-3 by approximately 28 days (Figures S2A and
D, Table S2) but had no effect against ALL-7 or ALL-19 (Figures
S2B–D, Table S2). ALL-7 and ALL-19 were previously shown to
be relatively resistant to DEX and VCR in vivo [17], and are
derived from patients who succumbed to their disease at 13 and 11
months following diagnosis, respectively (Table S1).
We next examined the efficacy of VCR (0.25 mg/kg), DEX
(7.5 mg/kg) and ASP (2500 U/kg) as single agents and in
combination against ALL-7 and ALL-19. Despite being attenu-
ated to a quarter of the maximum tolerated dose (MTD) VCR still
effectively delayed leukemia progression compared to control mice
by approximately 5 weeks in both xenografts (Figures S3A and E,
Table S2). At this dose DEX showed modest efficacy against ALL-
7, delaying its progression by approximately 4 weeks while ASP
was ineffective. However, the VXL combination treatment of
ALL-7 resulted in a LGD of 82.8 days, 18.5 days greater than the
sum of the LGDs for the individual drugs (Table S2). Similarly,
while single agents DEX and ASP remained ineffective in delaying
the progression of ALL-19, the VXL combination treatment
resulted in a LGD of 47.5 days, which was 11 days greater than
the sum of the LGDs for the individual drugs (Figures S3B, C and
E, Table S2). Unexpectedly, some of the mice in the VXL treated
group experienced toxicity, with only 3 mice reaching leukemia-
related events, while some mice treated with ASP alone also
exhibited mild weight loss. Therefore, and in consideration of the
aims of the study, the VCR, DEX and ASP doses were further
attenuated to 0.15 mg/kg, 5 mg/kg and 1000 U/kg, respectively.
VCR at a dose of 0.15 mg/kg was still effective against ALL-19
with a LGD of 19.4 days (Figure 2C, Table S2); DEX and ASP
were ineffective as single agents at the attenuated doses (Figures 2B
and D, Table S2). Importantly, these doses of DEX and ASP
effectively delayed the progression of the chemosensitive xenograft
ALL-3 (data not shown and Table S2). The VXL combination,
which was well tolerated, delayed the progression of ALL-19 by
33.9 days, which was 12.2 days greater than the sum of the LGDs
for the individual drugs (Figures 2E and F, Table 2 and Table S2).
In contrast to previous experiments in which higher drug doses
were used and mice were culled due to drug toxicity, all events in
this experiment were leukemia related.
We next examined the effect of the optimized VXL combina-
tion treatment against several other previously established BCP-
ALL and T-ALL xenografts. As shown in Figures 3 and 4, the
responses of the xenografts to the VXL combination treatment
varied. The chemosensitive T-ALL xenograft ALL-16 was the
most sensitive to treatment with VXL, with a LGD greater than
146.8 days and no leukemia related deaths (Figures 3D, Table 2),
while the Philadelphia chromosome-positive ALL-4, was only
delayed by approximately 23 days (Figure 3A, Table 2). Other
xenografts exhibited delays in leukemia progression intermediate
of ALL-16 and ALL-4 (Table 2). Interestingly, we observed that
LGDs measured following VXL combination treatment were
significantly higher for xenografts derived from long term survivors
(median of 99.7 days) than those derived from patients who died of
their disease (median of 46.2 days) (p=0.0159, Mann-Whitney
test) (Figure 4). Also, by setting an arbitrary cut-off value of 55
days, we obtained evidence of interdependence between the LGD
for the xenografts and patient clinical outcome (p=0.047, two
sided chi-square contingency test, data not shown).
Pharmacokinetic analysis of VCR, DEX and ASP in NOD/
SCID mice
We next undertook pharmacokinetic studies to establish
whether plasma drug concentrations achieved in mice were
clinically relevant and to determine if the disposition of a drug was
altered when administered in combination. Mice with established
leukemia (ALL-19) were treated with each drug as either a single
agent or in the triple combination and pharmacokinetic studies
were performed. The concentration-time plot for each drug as a
single agent and in combination is presented in Figure 5. For VCR
and ASP, a two-compartment model produced a reasonable fit to
the data from both single agent and combination groups
simultaneously (Figures 5A and 5C). No apparent difference






mL] Combination Index Values
CEM COG-LL-317 COG-LL-319 RS4-11
0.5 50 1 0.15 0.10 0.10 0.04
1.25 125 2.5 0.33 0.11 0.11 0.09
2.5 250 5 0.61 0.15 0.15 0.16
5 500 10 1.04 0.21 0.21 0.10
VCR, vincristine; DEX, dexamethasone; ASP, L-asparaginase.
doi:10.1371/journal.pone.0033894.t001
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(Table 3). For DEX, the one compartment pharmacokinetic
model adequately described the data shown in Figure 5B.
Administration of VXL increased the DEX area under the
concentration-time curve (AUC) approximately 2-fold and the
Cmax by 1.5-fold (Table 3).
VXL treatment regimen as a platform for the detection of
synergy in combination with novel drugs against
pediatric ALL
The VXL treatment was optimized so that additional drugs
could be used in combination with this platform in order to model
interactions with the induction-type regimen typical of ALL
therapy in the clinical setting. For this purpose we first selected
Figure 2. In vivo sensitivity of ALL-19 to low dose VCR, DEX and ASP. Female mice were engrafted with ALL-19 cells and treated with vehicle
(A); DEX (5 mg/kg) (B); VCR (0.15 mg/kg) (C); and ASP (1000 U/kg) (D); as single agents or the combination of the three drugs at the same doses
(VXL) (E). The %huCD45
+ cells in PB of individual mice (A–E); control vehicle-treated mice (dashed lines); drug-treated mice (solid lines). Kaplan-Meier
analysis of EFS (F) control (grey solid line), VCR (grey dashed line), DEX (black dashed line), ASP (black dotted line), VXL (solid black line). All events
were leukaemia-related. Shaded boxes represent the treatment period.
doi:10.1371/journal.pone.0033894.g002
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function of Bcl-2, Bcl-xL and Bcl-w and to induce apoptosis in a
variety of cancer cell types including leukemias [20,21,22]. We
have previously shown that ABT-737 potentiated the effect of the
VXL treatment [23] and interacted synergistically with ASP/
topotecan combination against chemoresistant xenografts ALL-7
and ALL-19 [24]. In the present study we tested the VXL/ABT-
737 combination against 3 additional chemoresistant ALL
xenografts (ALL-2, ALL-4 and ALL-8; derived from patients
who died of their disease) and 2 xenografts of intermediate
chemosensitivity (ALL-10 and ALL-17; derived from patients who
are currently in remission, Table S1). This drug combination
could not be tested on the other 3 highly chemosensitive
xenografts derived from long-term survivors (ALL-3, ALL-11
and ALL-16) because of the high efficacy of the VXL treatment
alone. ABT-737 significantly potentiated the effect of the VXL
combination treatment in the chemoresistant ALL xenografts,
from 6.4 days against ALL-4 to 13.5 days against ALL-2, above
what was predicted if the effects were additive (Figure 6, Table 2).
No correlations (Spearman) have been found between the Bcl-2
proteins expression and response to the VXL/ABT-737 combi-
nation treatment.
The VXL therapy was also combined with ATO, a standard
chemotherapeutic agent used in the treatment of acute promy-
elocytic leukemia, since a previous study suggested that ATO
reverses DEX resistance in ALL [25]. As demonstrated in Figure 7
and Table 4 ATO as a single agent had a small but statistically
significant effect in delaying the progression of only one (ALL-4) of
four ALL xenografts tested. When combined with VXL, ATO
significantly improved the progression delays of two (ALL-4 and
ALL-7) of four ALL xenografts tested, although the augmentation
of VXL efficacy by ATO appears unlikely to be of biological
significance.
Discussion
This study reports the optimization, based on pharmacokinetic
parameters, of an induction-type regimen for the preclinical
prioritization of new anti-cancer agents in combination with
Table 2. In vivo responses of ALL xenografts to ABT-737, VXL or VXL/ABT-737 combination treatments.
Xenograft Treatment




Significance vs VXL [P
value]
ALL-2 Control 19.7 (6) -
ABT-737 27.3 (8) 7.6 0.0236
VXL 78.6 (8) 58.9 ,0.0001
VXL/ABT-737 99.7 (7) 80.0 0.0002 0.0001
ALL-3 Control 15.8 (8) -
VXL .133.4 (8) .117.6 ,0.0001
ALL-4 Control 10.1 (8) -
ABT-737 8.5 (8) 0 0.025
VXL 32.9 (8) 22.8 0.0048
VXL/ABT-737 39.3 (8) 29.2 ,0.0001 0.0069
ALL-7 Control 12.7 (8) -
VXL 58.9 (8) 46.2 ,0.0001
ALL-8 Control 10.9 (8) -
ABT-737 10.7 (8) 0 1.0
VXL 64.6 (8) 53.7 ,0.0001
VXL/ABT-737 76.5 (7) 76.5 0.0001 0.0245
ALL-10 Control 12.5 (7) -
ABT-737 26.0 (8) 13.5 ,0.0001
VXL 71.8 (8) 59.3 ,0.0001
VXL/ABT-737 78.3 (8) 65.8 ,0.0001 0.0966
ALL-11 Control 19.3 (8) -
VXL 119 (10) 99.7 ,0.0001
ALL-16 Control 13.2 (8) -
VXL .160.0 (5) .146.8 ,0.0001
ALL-17 Control 15.1 (6) -
ABT-737 28.9 (8) 13.8 0.0005
VXL 72 (7) 56.9 0.0002
VXL/ABT-737 72 (7) 56.9 0.0002 0.3389
ALL-19 Control 6.9 (8) -
VXL 40.8 (7) 33.9 0.0002
Significant values are shown in bold.
doi:10.1371/journal.pone.0033894.t002
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useful to eliminate new drugs that are unlikely to provide any
benefit in the clinical management of ALL, and thereby avoid the
unnecessary treatment of pediatric patients. Desirable character-
istics of a preclinical drug testing xenograft model include that it:
(1) represents the human disease phenotypically and genetically; (2)
reflects the heterogeneity of the clinical disease; (3) exhibits high
take rates of engraftment and reproducible leukemia progression
within treatment groups; (4) is amenable to routine monitoring of
leukemia progression during and after drug treatment; (5) reflects
clinically relevant responses to established chemotherapeutic
drugs; and (6) takes into consideration differences in pharmaco-
kinetics of drugs between the selected species and humans and thus
assesses clinically equivalent doses, since increased host tolerance
Figure 3. In vivo sensitivity of ALL xenografts to VXL combination treatment. Female mice were engrafted with: ALL-4 (A); ALL-7 (B); ALL-11
(C); or ALL-16 (D); and treated with a combination of VCR (0.15 mg/kg), DEX (5 mg/kg) and ASP (1000 U/kg). The %huCD45
+ cells in PB of individual
mice (left panel) and Kaplan-Meier analysis of EFS (right panel). Control vehicle-treated mice (dashed lines); drug-treated mice (solid lines). Shaded
boxes represent the treatment period. No leukaemia related events were recorded for the drug treated group of ALL-16 engrafted mice.
doi:10.1371/journal.pone.0033894.g003
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pediatric ALL xenografts previously described by our group
adheres favorably to these criteria [17,18,26]. In the current study
we extend the utility of this model to multi-agent chemotherapy
consisting of a VXL induction-type regimen, and demonstrate its
usefulness for testing novel drugs, which could be incorporated
into induction/re-induction phases of treatment in order to
improve therapeutic outcome for high risk ALL patients. A
previous study by Ek et al. which used VCR/methylprednisolone/
ASP in combination to assess the efficacy of the anti-CD19
immunotoxin B43-PAP in a preclinical model of ALL demon-
strated the usefulness of testing new agents in combination with
established drugs. However, the clinical relevance of the doses
used in that model was unclear [27].
In this study we demonstrated that the cytotoxic effect of VXL
combination treatment was highly synergistic against ALL cell
lines in vitro and that this synergy was maintained over a broad
range of drug concentrations. More importantly, using these ALL
xenograft models we have shown that in vivo doses of DEX and
ASP that, individually, caused no delay in progression of
aggressive and chemoresistant xenografts (ALL-7 and ALL-19),
resulted in synergistic interactions when combined with VCR. The
reason for the observed synergy is presently unknown, however it
could be explained, at least in part, by the finding that the
combination of DEX with VCR and ASP resulted in a
significantly higher exposure to DEX when compared to DEX
alone, when administered at the same dose. This observation is
consistent with a recently published study that examined DEX
pharmacokinetics in pediatric ALL patients [28]. The authors
have reported that while DEX pharmacokinetics were highly
varied between patients, co-administration of ASP decreased
clearance of DEX resulting in the increased systemic exposure to
the drug [29]. The mechanism responsible for decreased clearance
of DEX is not clear but is positively correlated with levels of serum
albumin.
In addition, the synergistic effect of the VXL combination may
also occur at the cellular level, where it could be due to the non-
overlapping mechanisms of cytotoxicity and/or resistance to the 3
drugs. VCR binds to the b subunit of the a/b-tubulin heterodimer
and suppresses microtubule dynamics, blocks cell cycle progression
at the G2/M phase and induces apoptosis [30]. A common
mechanism of VCR resistance involves reduced intracellular drug
accumulation due to overexpression of multidrug transporters such
as MDR1 and MRP1 [31]. Glucocorticoid-induced apoptosis of
lymphocytes is mediated via the cytoplasmic glucocorticoid
receptor (GR), and resistance is frequently associated with
mutation or decreased expression of the GR, or of interruption of
downstream apoptotic pathways [32,33]. ASP catalyzes the
hydrolysis of L-asparagine to L-aspartic acid and ammonia, which
results in depletion of serum asparagine and starvation of ALL
cells by depriving them of an essential amino acid [34]. Increased
expression of asparagine synthetase protein appears to be one
mechanism of ALL resistance to ASP [35].
We have previously shown that the response of a panel of
xenografts to single-agent DEX (15 mg/kg) and VCR (0.5 mg/
kg), at higher doses than those used in this study, correlated well
with patient outcome [17]. Moreover, ALL-7 and ALL-19, which
were derived from patients who died from their disease within 13
months of diagnosis, were inherently more resistant to both drugs
when compared to ALL-3, which was derived from a patient who
remains in remission more than 17 years following diagnosis. An
interesting finding of the current study is that the magnitude of the
response to the VXL combination therapy also correlates with
patient outcome. The median LGD recorded for a cohort of
xenografts derived from long term survivors was over 2-fold higher
than that observed for xenografts derived from patients who died
of their disease. This result provides further evidence to support
Figure 4. LGD in response to VXL treatment in xenografts
stratifies according to patient outcome. Median LGD obtained by
VXL treatment for a panel of ALL xenografts derived from long term
survivors (Alive) and from patients who died of their disease (DOD).
There is evidence that the two groups are different (p=0.0159) by
Mann-Whitney two tailed test.
doi:10.1371/journal.pone.0033894.g004
Figure 5. Pharmacokinetic analysis of VCR, DEX and ASP in
leukemias bearing NOD/SCID mice. Engrafted female mice (ALL-
19) were treated with VCR (0.15 mg/kg), DEX (5 mg/kg), ASP (1000 U/
kg) or their combination (VXL) at the same doses. Three mice each were
sacrificed at specified time points and drug concentrations in plasma
for VCR (A); DEX (B); and ASP (C) in the single agent or combination
treatment were assessed as described in Materials and Methods.
doi:10.1371/journal.pone.0033894.g005
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However, it should be noted that the cohort of xenografts used in
this study was small and heterogeneous, and that the patients from
whom the xenografts were derived were not always treated on
identical induction protocols. Therefore, further validation using a
larger cohort of xenografts derived from patients treated on the
same protocol is warranted.
While VCR, DEX and ASP have been in clinical use for almost
50 years, comprehensive pharmacokinetic studies of these drugs in
patients are lacking. Furthermore, pharmacokinetic data of these
drugs in murine models are even scarcer. Retrospective analysis of
systemic exposures from preclinical and clinical data suggests that
these are crucial in determining drug efficacy. Due to a lack of
pharmacokinetic data it is a common practice to evaluate efficacy
of drugs at their MTD rather than at clinically equivalent doses.
However, differences in absorption, distribution, metabolism and
excretion of drugs could vary considerably between species,
resulting in different systemic exposures to a drug, thus affecting
therapeutic efficacy. Frequently, the MTD of drugs are higher for
mice than for humans [12,13] and consequently pre-clinical
models are often criticized for overestimating the efficacy of
chemotherapeutic agents. Therefore, in order to confirm the
clinical relevance of this induction type regimen it was important
to establish whether the plasma drug exposures in mice were
comparable to those achievable in humans. Studies in pediatric
ALL patients have revealed that the systemic exposure to VCR
following treatment at 2.0 mg/m
2 as an intravenous bolus varied
considerably among patients ranging from 0.9 to 14.9 mg/L*min
in one study [36] and from 0.4–7.5 mg/L*min in another study
[37] with median exposures of 5.4 and 2.8 mg/L*min, respec-
tively. Even though in our study a single dose of VCR (0.15 mg/
kg) administered to female NOD/SCID mice engrafted with a
BCP-ALL xenograft resulted in a lower median systemic exposure
to this drug (1.6 mg/L*min) than those reported in humans, this
value falls well within the range recorded for patients with ALL.
Reported pharmacokinetic parameters for DEX vary consider-
ably between studies. In pediatric patients a moderate dose of
8 mg/m
2/day resulted in mean AUC value of 167 ng/mL*h [28].
In other studies in adults the AUC values were not reported,
however from their pharmacokinetic parameters we can estimate
that a single dose of 20 mg DEX intravenously (i.v.) or 300 mg
DEX administered orally resulted in systemic exposures of
2000 ng/mL*h [38] and 8000 ng/mL*h, respectively [39].
Overall we conclude that systemic exposure to DEX in our model
falls within the upper range of what has been reported in patients.
The dose, schedule, preparation and the route of administration
of ASP, all of which influence pharmacokinetics and pharmaco-
dynamics of the drug, vary considerably between protocols used in
the clinic to treat pediatric ALL patients. Furthermore, since ASP
is immunogenic, the presence or absence of anti-ASP antibodies as
well as their titer, are known to increase the variability of ASP
pharmacokinetic profiles in patients. The most commonly used
treatment protocols utilize ASP derived from either Escherichia coli
or Erwinia chrysanthemi, which are typically administered i.v. or
intramuscularly (i.m.) 2–3 times a week, at doses ranging from
5000–12000 U/m
2 [40], although protocols using E. chrysanthemi
derived ASP at doses as high as 30000 U/m
2 administered daily
for 10 days have been reported [41]. A recent clinical trial has
demonstrated that following a low dose ASP (5000 U/m
2)
treatment the systemic exposure to the drug varied considerably
among patients ranging between 38.6 and 83.8 U*h/mL [42].
The AUC value (87.0 U*h/mL) in our model falls only slightly
above this range and since the clinical study used a low dose of
ASP we conclude that the systemic exposure to ASP achieved in
our preclinical model reflects clinical scenarios.
ABT-737 and the closely related clinical homolog ABT-263
(Navitoclax) are BH3-mimetics, which inhibit the anti-apoptotic
Bcl-2 family members, Bcl-2, Bcl-xL and Bcl-w [20,43]. The
activity of both drugs has been extensively evaluated in a variety of
preclinical cancer models, including ALL xenografts
[20,21,23,24,43,44,45,46]. These studies have demonstrated that
both drugs have potent single agent in vitro and in vivo activity
against a variety of cancer cell lines and primary cells including
ALL. Furthermore, both compounds significantly potentiate the
efficacy of established and novel chemotherapeutic agents. ABT-
263 is currently being evaluated in phase 1/2 clinical trials in
patents with hematological malignancies or small cell lung cancer
[47,48]. In the present study we used the VXL treatment regimen
in combination with a low dose of ABT-737 in order to assess its
applicability as a platform for testing of novel drugs. The
incorporation of ABT-737 into the VXL combination resulted
in therapy that was well tolerated, thus providing evidence that
additional drugs can be administered in conjunction with VXL
treatment using this ALL xenograft model. Furthermore, in
agreement with previously published data [23] we have shown that
ABT-737 potentiated the effects of VXL therapy in resistant ALL
xenografts, again strengthening the case for the incorporation of its
clinical equivalent into multi-agent clinical trials in pediatric ALL
patients. While delineating the mechanisms responsible for
synergistic interactions between VXL and ABT-737 is beyond
the scope of this study, we have previously suggested that
downregulation of Mcl-1 following ASP treatment is a contribut-
ing factor [24].
A recent in vitro study utilizing patient samples has suggested that
combining low dose ATO with DEX may improve the treatment
of DEX-resistant ALL [25]. In the current study we combined
VXL with ATO and tested its efficacy against several DEX
resistant ALL xenografts in vivo and found that ATO only
marginally delayed leukemia progression in two out of four
xenografts tested. Therefore, our data support the reported limited
clinical activity of ATO against ALL as a single agent [49], and
provide limited rationale for its incorporation into combination
treatment regimens in this disease.
Table 3. Estimated pharmacokinetic parameters.
{Parameter Single Agent VXL Combination
VCR 0.15 mg/kg VCR 0.15 mg/kg
AUC0-‘ (mg/L*min) 1.60 1.75
Cmax (ng/mL) 6.2 8.7
Tmax (h) 1 0.5
DEX 5 mg/kg DEX 5 mg/kg
AUC0-‘ (ng*h/mL) 3279.05 6792.95
Cmax (ng/mL) 1760.73 2849.02
Tmax (h) 0.16 0.25
ASP 1000 U/kg ASP 1000 U/kg
AUC0-‘ (U*h/mL) 87.02 99.44
Cmax (U/mL) 8.27 8.90
Tmax (h) 2.21 1.97
{Abbreviations. AUC0-‘: Area under the concentration-time curve from zero to
infinity; Cmax: actual maximum concentration observed after drug
administration; Tmax: time of maximum drug concentration.
doi:10.1371/journal.pone.0033894.t003
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33894Figure 6. In vivo sensitivity of ALL xenografts to VXL and VXL/ABT-737 combination treatments. Female mice were engrafted with: ALL-2
(A); ALL-8 (B); ALL-10 (C); or ALL-17 (D) and treated with a diluent vehicle (controls, dashed black lines), ABT-737 (25 mg/kg, solid grey lines), VXL
combination (solid black lines), or VXL+ABT-737 quadruple combination (dashed grey lines). Engraftment kinetics indicated by %huCD45
+ cells in PB
of individual mice (left panel) and Kaplan-Meier survival curves (EFS) (right panel) are shown. Shaded boxes represent the treatment period. All events
were leukemia-related except for 1 and 4 in the VXL/ABT-737-treated group of the ALL-8, and ALL-10, respectively. In the ALL-17 quadruple drug
combination cohort all mice were culled due to leukemia or toxicity unrelated morbidity.
doi:10.1371/journal.pone.0033894.g006
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33894In summary, we have described the optimization of a clinically
relevant and robust combination chemotherapy regimen of VXL
in the ALL NOD/SCID xenograft model. Using this induction/
re-induction-type regimen we have further demonstrated its
applicability for screening novel drugs for the identification of
synergistic interactions that may warrant their advancement into
clinical trials in high risk and relapsed ALL patients.
Figure 7. In vivo sensitivity of ALL xenografts to VXL and VXL/ATO combination treatments. Female mice were engrafted with: ALL-4 (A);
ALL-7 (B); ALL-8 (C); or ALL-19 (D) and treated with a diluent vehicle (controls, dashed black lines), ATO (2.5 mg/kg, solid grey lines), VXL combination
(solid black lines), or VXL+ATO quadruple combination (dashed grey lines). Engraftment kinetics indicated by %huCD45
+ cells in PB of individual mice
(left panel) and Kaplan-Meier survival curves (EFS) (right panel) are shown. Shaded boxes represent the treatment period.
doi:10.1371/journal.pone.0033894.g007
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In vitro cell culture and cytotoxicity assays
All cell culture was carried out at 37uC with 5% O2 (equivalent
to the physiological hypoxia found in bone marrow) and 5% CO2
[50]. A cell line from human T-cell leukemia established from a
child at relapse (COG-LL-317) and a human pre-B leukemia cells
established from a child at diagnosis prior to therapy (COG-LL-
319) were obtained from the Children’s Oncology Group (COG)
Cell Line and Xenograft Repository (www.cogcell.org) [23]. They
were maintained in Iscove’s Modified Dulbecco’s Medium
(Cambrex, Walkersville, MD) supplemented with 3 mM L-
glutamine, 5 mg/mL insulin and 20% heat-inactivated fetal bovine
serum (FBS). The pre-B ALL cell line RS4-11 and the T-
lymphoblast ALL cell line CEM were cultured in RPMI-1640
medium (Mediatech Inc., Herdon, VA) supplemented with 10%
heat-inactivated FBS.
The cytotoxic effects of VCR, DEX and ASP were determined
using the DIMSCAN assay system [50]. The drug concentration
ranges for the assay were 0.5–10 ng/mL for VCR, 50–500 nM for
DEX and 1–10 U/mL for ASP at fixed ratios. Cells were treated
over 48 h (RS4-11) or 72 h (CEM, COG-LL-317 and COG-LL-
319), following which fluorescein diacetate and eosin Y were
added to final concentrations of 10 mg/mL and 0.1% (w/v),
respectively. Fluorescence was measured using digital image
microscopy, and the fractional survival of treated cells was
determined compared to that of controls. Combination Indices
(CIs) were calculated using Calcusyn (Biosoft, Cambridge, UK) as
previously described [50]. With this method, a CI,0.3 indicates
strong synergy, 0.3–0.7 synergy, 0.7–0.85 moderate synergy, 0.85–
0.9 slight synergy, 0.9–1.1 additivity, 1.1–1.2 slight antagonism,
1.2–1.45 moderate antagonism, 1.45–3.3 antagonism, .3.3 strong
antagonism.
Ethics statement
All mice were maintained under barrier conditions and
experiments were conducted using protocols and conditions
approved by the Animal Care and Ethics Committee of the
University of New South Wales (ACEC: 04/124b and 07/157b).
In vivo xenograft model of childhood ALL
NOD/SCID (NOD.CB17-Prkdc
scid/J) mice at 6–8 weeks of age
were obtained from the Institute of Medical and Veterinary
Science, Adelaide, SA, Australia. The establishment of a panel of
continuous xenografts from childhood ALL biopsies in NOD/
SCID mice and assessment of their in vivo responses to DEX and
VCR have previously been described in detail elsewhere [17,18].
Patient demographics, cytogenetic and clinical data, from whom
the xenografts were established are represented in Table S1.
Leukemia engraftment was monitored by flow cytometric
quantification of the proportion of human CD45-positive
(huCD45
+) cells versus total murine CD45
+ cells in the PB, bone
marrow, spleen and/or liver, as described previously [17,18].
For in vivo drug treatments, groups of 6–8 mice were inoculated
with 2.5–5610
6 ALL mononuclear cells purified from spleens of
previously engrafted mice. When the median %huCD45
+ cells in
the PB reached 1%, mice were randomized to receive drug or
vehicle treatment. All drugs were administered by intraperitoneal
injection (i.p.). Drug schedules were as follows: VCR (Sigma-
Aldrich, Inc., St. Louis, MO, U.S.A.) once a week for 4 weeks;
DEX and ATO (Sigma-Aldrich, Inc.), ASP (LeunaseH, Aventis,
Lane Cove, NSW, Australia), or ABT-737 (kindly provided by
Abbott Laboratories, IL, U.S.A.) Monday to Friday for 4 weeks.
For VXL/ABT-737 combination treatments VXL and ABT-737
were administered 6–8 hours apart.
Event-free survival (EFS) was calculated for each mouse as the
number of days following randomization (6 days before treatment
initiation) until the %huCD45
+ cells in the PB reached 25%, or
Table 4. In vivo responses of ALL xenografts to ATO, VXL or VXL/ATO combination treatments.
Xenograft Treatment Median EFS [days] (number of mice) LGD [days]
Significance vs control [P
value]
Significance vs VXL [P
value]
ALL-4 Control 5.1 (8) -
ATO 10.5 (8) 5.4 0.0075
VXL 40.3 (7) 35.2 0.0001
VXL/ATO 42.3 (7) 37.2 0.0001 0.0252
ALL-7 Control 11.5 (7) -
ATO 10.8 (7) 0 0.6734
VXL 63.3 (6) 51.8 0.0004
VXL/ATO 70.8 (7) 59.3 0.0001 0.0012
ALL-8 Control 10.3 (7) -
ATO 12.4 (7) 2.1 0.6399
VXL 65.6 (7) 55.3 0.0001
VXL/ATO 68.4 (6) 58.1 0.0004 0.1499
ALL-19 Control 9.3 (7) -
ATO 11.9 (9) 2.6 0.115
VXL 55.2 (8) 45.9 0.0270
VXL/ATO 52.9 (9) 43.6 0.0015 0.9394
Significant values are shown in bold.
doi:10.1371/journal.pone.0033894.t004
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PLoS ONE | www.plosone.org 11 March 2012 | Volume 7 | Issue 3 | e33894until mice experienced drug or leukemia-related morbidity (weight
loss, lethargy, ruffled fur). EFS values for different treatments were
compared by Kaplan-Meier survival curves [51]. For comparisons
between different xenografts and between responses to various
drug treatments, the median EFS of control mice was subtracted
from the median EFS of drug-treated mice to generate a leukemia
growth delay (LGD).
Synergistic, additive, or antagonistic drug interactions in vivo
were estimated theoretically by the summation of individual LGD
values [52]. This method assumes that the delay in tumor
progression induced by a defined period of drug treatment is
proportional to the log cell kill. The combined effect of more than
one drug is the summation of individual delay times, assuming
independence, and an additive effect is obtained when the LGD
for a combination of drugs is equal to the sum of LGDs for each
individual drug. An observed LGD for a combination of drugs that
is greater than the sum of the single agent’s LGDs indicates
synergy, while an observed delay less than the sum indicates
antagonism.
Pharmacokinetic study
NOD/SCID mice engrafted with ALL-19 were treated i.p. with
single agents VCR (0.15 mg/kg), DEX (5 mg/kg), ASP (1000 U/
kg) or a combination of these three drugs at the same doses. Three
mice contributed one blood sample via terminal cardiac puncture at
eachof the followingtime points after drug administration: 0, 0.5, 1,
2, 4, 6, 12, and 24 h, and the plasma was stored at 280uC until
analysis. Drug concentrations were measured using previously
published methods validated in our laboratory (see Methods S1).
All concentration-time data from the single agent group of mice
and the drug combination group of mice were analyzed
simultaneously. Nonlinear mixed-effects modeling with NON-
MEM VII software [53] was used to fit an appropriate
compartmental model to the concentration-time data. The effect
of the drug combination was assessed by adding the drug
combination as a covariate on the CL parameter and assessing
the change in the objective function value. A decrease $3.8 units
indicates that the covariate model significantly increases the model
fit to the data (p.0.05).
Statistical methods
Median EFS values were obtained for control and treated
cohorts, the difference between these medians (LGD) was
calculated for each treatment group. Kaplan-Meier survival curves
[51] were generated based on the event definition of 25% of
huCD45
+ cells out of the number of total circulating leukocytes in
PB. The exact log-rank test (using Graphpad Prism 5.02) was used
to compare EFS distributions between treatment and control
groups (two tailed). P-values#0.05 were considered evidence of
significant differences. The non-parametric Mann-Whitney test
was used to compare non-normally distributed datasets. Two sided
contingency testing (chi square) was used for testing interdepen-
dency of classification above or below a selected threshold of 55
days of LGD for xenografts generated from patient samples of
good or poor clinical outcome.
Supporting Information
Methods S1 Detailed description of analytical method-
ology used for the pharmacokinetic study of the drugs
VCR, DEX and ASP in mice (with references).
(DOC)
Figure S1 Time-course and tissue distribution of en-
graftment of ALL-19 in NOD/SCID mice. Mice were
inoculated with 5610
6 ALL-19 cells i.v. At weekly intervals two
mice were culled and the %huCD45
+ cells relative to total
(human+murine) CD45
+ cells were monitored in peripheral blood
(open circles), spleen (closed squares), bone marrow (closed circles)
and liver (open triangles) by flow cytometry.
(TIF)
Figure S2 In vivo responses of BCP-ALL xenografts to
ASP. Male NOD/SCID mice were inoculated with ALL-3
(A); ALL-7 (B); and ALL-19 (C) cells, monitored for
engraftment, and treated with saline (dashed lines) or
2500 U/kg of ASP (solid lines). Each line represents a single
mouse. EFS represented by Kaplan-Meier analysis (D) for control
(gray lines) or ASP-treated (black lines) mice, for ALL-3 (solid
lines), ALL-7 (dotted lines) and ALL-19 (dashed lines). Shaded
boxes represent ASP or vehicle treatment periods.
(TIF)
Figure S3 In vivo responses of ALL-19 to moderate dose
VCR, DEX and ASP. Female mice were inoculated with ALL-
19 cells, monitored for engraftment and treated with diluent
(dashed lines) or with drugs (solid line): VCR (0.25 mg/kg) (A);
DEX (7.5 mg/kg) (B); ASP (2500 U/kg) (C); or the combination
of the three drugs (VXL) at the same doses (D). The %huCD45
+
cells in PB was measured at weekly intervals. Kaplan-Meier
analysis of EFS (E) of controls (gray dashed line), VCR treated
(gray solid line), DEX treated (black dashed line), ASP treated
(black dotted line) and VXL treated (black solid line) groups. The
two early events in the VXL-treated group were not leukemia-
related. Shaded boxes represent treatment period.
(TIF)
Table S1 Detailed demographic, cytogenetic and clini-
cal characteristics of the patients from whom biopsy
samples were obtained for establishment of the differ-
ent xenografts used in this study.
(DOC)
Table S2 In vivo responses of xenografts ALL-3, ALL-7
and ALL-19 induced by treatment with either VCR,
DEX, ASP or their combination at different doses.
Median EFS and corresponding LGD (both in days) are shown.
(DOC)
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